Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. / Engsbro, Anne Line; Stensvold, C Rune; Nielsen, Henrik V; Bytzer, Peter.

I: American Journal of Tropical Medicine and Hygiene, Bind 87, Nr. 6, 12.2012, s. 1046-52.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Engsbro, AL, Stensvold, CR, Nielsen, HV & Bytzer, P 2012, 'Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome', American Journal of Tropical Medicine and Hygiene, bind 87, nr. 6, s. 1046-52. https://doi.org/10.4269/ajtmh.2012.11-0761

APA

Engsbro, A. L., Stensvold, C. R., Nielsen, H. V., & Bytzer, P. (2012). Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. American Journal of Tropical Medicine and Hygiene, 87(6), 1046-52. https://doi.org/10.4269/ajtmh.2012.11-0761

Vancouver

Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P. Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. American Journal of Tropical Medicine and Hygiene. 2012 dec.;87(6):1046-52. https://doi.org/10.4269/ajtmh.2012.11-0761

Author

Engsbro, Anne Line ; Stensvold, C Rune ; Nielsen, Henrik V ; Bytzer, Peter. / Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. I: American Journal of Tropical Medicine and Hygiene. 2012 ; Bind 87, Nr. 6. s. 1046-52.

Bibtex

@article{8d06de6861304dc1981da094cce75ebe,
title = "Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome",
abstract = "The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.",
keywords = "Adult, Antiprotozoal Agents, Denmark, Dientamoeba, Dientamoebiasis, Feces, Female, Humans, Irritable Bowel Syndrome, Male, Metronidazole",
author = "Engsbro, {Anne Line} and Stensvold, {C Rune} and Nielsen, {Henrik V} and Peter Bytzer",
year = "2012",
month = dec,
doi = "10.4269/ajtmh.2012.11-0761",
language = "English",
volume = "87",
pages = "1046--52",
journal = "Journal. National Malaria Society",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "6",

}

RIS

TY - JOUR

T1 - Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome

AU - Engsbro, Anne Line

AU - Stensvold, C Rune

AU - Nielsen, Henrik V

AU - Bytzer, Peter

PY - 2012/12

Y1 - 2012/12

N2 - The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.

AB - The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.

KW - Adult

KW - Antiprotozoal Agents

KW - Denmark

KW - Dientamoeba

KW - Dientamoebiasis

KW - Feces

KW - Female

KW - Humans

KW - Irritable Bowel Syndrome

KW - Male

KW - Metronidazole

U2 - 10.4269/ajtmh.2012.11-0761

DO - 10.4269/ajtmh.2012.11-0761

M3 - Journal article

C2 - 23091195

VL - 87

SP - 1046

EP - 1052

JO - Journal. National Malaria Society

JF - Journal. National Malaria Society

SN - 0002-9637

IS - 6

ER -

ID: 47892620